A comprehensive view of Phase 2 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sage Therapeutics announces topline results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the treatment of mild cognitive impairment in Parkinson’s disease
Published: April 17, 2024 by Sage Therapeutics
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
Published: April 07, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Moderna reports its investigational injectable mRNA therapy mRNA-3927 shows potential clinical benefits and infrequent side effects in phase 1/2 study; therapy is aimed at treating inherited metabolic disorder propionic acidemia
Published: April 03, 2024 by Moderna Inc.
Novo Nordisk acquires Cardior Pharmaceuticals for up to €1.025B, aiming to strengthen its portfolio in cardiovascular disease treatments; deal includes Cardior's RNA-targeting therapies and its Phase 2 lead compound CDR132L for heart failure
Published: March 25, 2024 by GlobeNewswire Europe

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count